Cd4 + T Cell Matters in Tumor Immunity

Velders, Markwin P.; Markiewicz, Mary A.; Eiben, Gretchen L.; Kast, W. Martin

doi:10.1080/08830180305220

Cited by 32 publications

(33 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the clinical utility of candidate vaccine antigens has typically been evaluated in part by examining the presence of antigen-specific CD8 T cells in the peripheral blood. There is increasing evidence to suggest that antigen-specific CD4 T cell responses are also important to induce effective and sustained antitumor responses [26]. In preliminary experiments, we have been able to detect the presence of CD4 T cells that recognize prostein-derived epitopes in PBMC of healthy individuals, further supporting the development of prostein in vaccine-based immunotherapy strategies for prostate cancer.…”

Section: Discussionsupporting

confidence: 51%

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue‐specific vaccine candidate

Friedman¹,

Spies²,

Kalos³

2004

Eur J Immunol

View full text Add to dashboard Cite

Prostein is a prostate tissue-specific protein that is uniquely and abundantly expressed in normal and cancerous prostate tissues. Due to this expression profile, we examined the immunogenicity of prostein as a potential vaccine candidate for prostate cancer. To determine the presence of CD8 T cells specific for naturally processed prostein-derived epitopes in healthy individuals, we developed and applied an in vitro stimulation protocol. Using this protocol, we identified CD8 T cells specific for prostein in the peripheral blood of a male and a female donor. Prostein-specific CD8 T cell clones specifically recognized prosteinexpressing targets, including prostate tumor cell lines expressing the relevant HLA alleles. CD8 T cell clones isolated from the male donor were significantly less effective in recognizing target cells compared to cells isolated from the female donor and appeared to recognize subdominant epitopes. The identification of a prostein-specific CD8 T cell repertoire supports the development of prostein in vaccination strategies against prostate cancer. Furthermore, the naturally processed peptide epitopes identified provide tools for the development of peptide-based vaccination strategies against prostate cancer and for monitoring of prostein-specific responses in vaccinated patients.

show abstract

Section: Discussionsupporting

confidence: 51%

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue‐specific vaccine candidate

Friedman¹,

Spies²,

Kalos³

2004

Eur J Immunol

View full text Add to dashboard Cite

show abstract

“…18 The CD4 + / CD8a + /tcTCR/z + T lymphocytes that exert the described immune functions may also exert help to generate CD8 + CTL in vivo as well as memory responses. 39 …”

Section: Tcr Transfer To Cd4 + Cells Requires Cd8amentioning

confidence: 99%

Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α

Willemsen¹,

Ronteltap²,

Heuveling³

et al. 2004

Gene Ther

View full text Add to dashboard Cite

“…The cytolytic activity of CD8 + T cells exerts a direct anti-tumor eVect [66]. CD4 + T cells participate through the activation and maintenance of CD8 + T cells and the recruitment of inXammatory cells such as macrophages, granulocytes, natural killer (NK) cells, and B cells [24,47,51,93,131].…”

Section: The Immune System Can Reject Tumorsmentioning

confidence: 99%

Targets for active immunotherapy against pediatric solid tumors

Jacobs

Coulie

Figdor

et al. 2008

Cancer Immunol Immunother

View full text Add to dashboard Cite

The potential role of antibodies and T lymphocytes in the eradication of cancer has been demonstrated in numerous animal models and clinical trials. In the last decennia new strategies have been developed for the use of tumor-speciWc T cells and antibodies in cancer therapy. EVective anti-tumor immunotherapy requires the identiWcation of suitable target antigens. The expression of tumorspeciWc antigens has been extensively studied for most types of adult tumors. Pediatric patients should be excellent candidates for immunotherapy since their immune system is more potent and Xexible as compared to that of adults. So far, these patients do not beneWt enough from the progresses in cancer immunotherapy, and one of the reasons is the paucity of tumor-speciWc antigens identiWed on pediatric tumors. In this review we discuss the current status of cancer immunotherapy in children, focusing on the identiWcation of tumor-speciWc antigens on pediatric solid tumors.

show abstract

Cd4 + T Cell Matters in Tumor Immunity

Cited by 32 publications

References 96 publications

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue‐specific vaccine candidate

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue‐specific vaccine candidate

Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α

Targets for active immunotherapy against pediatric solid tumors

Contact Info

Product

Resources

About